Spero Therapeutics Net Worth
Spero Therapeutics Net Worth Breakdown | SPRO |
Spero Therapeutics Net Worth Analysis
Spero Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Spero Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Spero Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Spero Therapeutics' net worth analysis. One common approach is to calculate Spero Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Spero Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Spero Therapeutics' net worth. This approach calculates the present value of Spero Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Spero Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Spero Therapeutics' net worth. This involves comparing Spero Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Spero Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Spero Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spero Therapeutics' net worth research are outlined below:
| Spero Therapeutics generated a negative expected return over the last 90 days | |
| Spero Therapeutics has some characteristics of a very speculative penny stock | |
| Spero Therapeutics has high historical volatility and very poor performance | |
| Spero Therapeutics currently holds about 45.4 M in cash with (32.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: UPDATE -- Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference |
Spero Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spero Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spero Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Spero Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Spero Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Spero Therapeutics backward and forwards among themselves. Spero Therapeutics' institutional investor refers to the entity that pools money to purchase Spero Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 148.9 K | Dafna Capital Management Llc | 2024-12-31 | 125 K | Northern Trust Corp | 2024-12-31 | 86.4 K | Citadel Advisors Llc | 2024-09-30 | 81.4 K | Squarepoint Ops Llc | 2024-12-31 | 55.1 K | Jane Street Group Llc | 2024-12-31 | 52.9 K | Prudential Financial Inc | 2024-12-31 | 49.2 K | Virtu Financial Llc | 2024-12-31 | 46 K | Xtx Topco Ltd | 2024-12-31 | 30.1 K | Anson Funds Management Lp | 2024-12-31 | 3.8 M | Vanguard Group Inc | 2024-12-31 | 1.8 M |
Follow Spero Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.48 M.Market Cap |
|
Project Spero Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.11 | 0.12 | |
| Return On Equity | 0.19 | 0.20 |
When accessing Spero Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Spero Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spero Therapeutics' profitability and make more informed investment decisions.
Evaluate Spero Therapeutics' management efficiency
As of the 26th of February 2025, Return On Tangible Assets is likely to grow to 0.12. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Spero Therapeutics' Return On Assets are very stable compared to the past year. As of the 26th of February 2025, Asset Turnover is likely to grow to 0.50, while Total Assets are likely to drop about 119.9 M. Spero Therapeutics' management efficiency ratios could be used to measure how well Spero Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.33 | 2.22 | |
| Tangible Book Value Per Share | 2.33 | 2.22 | |
| Enterprise Value Over EBITDA | 0.23 | 0.25 | |
| Price Book Value Ratio | 0.83 | 0.79 | |
| Enterprise Value Multiple | 0.23 | 0.25 | |
| Price Fair Value | 0.83 | 0.79 | |
| Enterprise Value | 6 M | 5.7 M |
The strategic initiatives led by Spero Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.1389 | Revenue | Quarterly Revenue Growth (0.47) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spero Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spero Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spero Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spero Therapeutics time-series forecasting models is one of many Spero Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Spero Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Spero Therapeutics Earnings per Share Projection vs Actual
Spero Therapeutics Corporate Management
| Satyavrat CFA | CFO Treasurer | Profile | |
| James Brady | Chief Officer | Profile | |
| Ted Jenkins | VP Relations | Profile | |
| Ian Critchley | Head Microbiology | Profile | |
| Susannah Walpole | Head Operations | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.